<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320312460899</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320312460899</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Neuropathic pain-attenuating potential of aliskiren in chronic constriction injury model in rats</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kukkar</surname><given-names>Ankesh</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Singh</surname><given-names>Nirmal</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Jaggi</surname><given-names>Amteshwar S</given-names></name>
</contrib>
<aff id="aff1-1470320312460899">Department of Pharmaceutical Sciences and Drug Research, Punjabi University, India</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1470320312460899">Amteshwar S Jaggi, Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala-147002, Punjab, India. Email: <email>amteshwarjaggi@yahoo.co.in</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>14</volume>
<issue>2</issue>
<fpage>116</fpage>
<lpage>123</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The present study was designed to investigate the potential of aliskiren, a direct renin inhibitor, in chronic constriction injury (CCI)-induced neuropathic pain in rats. Neuropathic pain was induced by placing four loose ligatures around the sciatic nerve. Acetone drop, von Frey hair, pin-prick and hot plate tests were performed to assess cold allodynia, mechanical allodynia, mechanical and heat hyperalgesia, respectively. The levels of Tumor necrosis factor-alpha (TNF-α) were measured in the sciatic nerve as an inflammatory marker. CCI was associated with the development of cold allodynia, mechanical allodynia, mechanical and heat hyperalgesia along with a rise in the levels of Tumor necrosis factor-alpha (TNF-α). Administration of aliskiren (25 or 50 mg/kg intraperitoneal (i.p.)) for 14 days in CCI-subjected rats significantly attenuated CCI-induced pain-related behavior and rise in TNF-α level. It may be concluded that aliskiren-mediated anti-inflammatory actions may be responsible for its beneficial effects in neuropathic pain in rats.</p>
</abstract>
<kwd-group>
<kwd>Chronic constriction injury</kwd>
<kwd>sciatic nerve ligation</kwd>
<kwd>aliskiren</kwd>
<kwd>inflammation</kwd>
<kwd>neuropathic pain</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1470320312460899" sec-type="intro">
<title>Introduction</title>
<p>Neuropathic pain has been described as the ‘most terrible of all tortures which a nerve wound may inflict’ and arises as a consequence of nerve injury either in the peripheral or central nervous system. Following peripheral nerve injury, a cascade of events in the primary afferents leads to peripheral sensitization resulting in spontaneous nociceptor activity, decreased threshold and increased response to supra-threshold stimuli. Neuropathic pain treatment is in the early stages of development, with many goals yet to be achieved.<sup><xref ref-type="bibr" rid="bibr1-1470320312460899">1</xref></sup> Consequently, there is still a considerable need to explore novel treatment modalities for neuropathic pain management.</p>
<p>The renin-angiotensin-aldosterone system plays an important role in regulating blood pressure, fluid volume and electrolyte balance.<sup><xref ref-type="bibr" rid="bibr2-1470320312460899">2</xref></sup> However, its over-activation leads to the development of various diseases including primary hypertension and chronic kidney disease, diabetic nephropathy, atherosclerosis and metabolic syndrome.<sup><xref ref-type="bibr" rid="bibr3-1470320312460899">3</xref><xref ref-type="bibr" rid="bibr4-1470320312460899"/><xref ref-type="bibr" rid="bibr5-1470320312460899"/>–<xref ref-type="bibr" rid="bibr6-1470320312460899">6</xref></sup> The blocking of the renin-angiotensin-aldosterone pathway is an important approach in various neurodegenerative diseases and conditions such as migraine pain, nociceptive pain and pancreatic pain.<sup><xref ref-type="bibr" rid="bibr7-1470320312460899">7</xref>–<xref ref-type="bibr" rid="bibr9-1470320312460899">9</xref></sup> Aliskiren blocks the renin-angiotensin-aldosterone system by directly inhibiting renin and, subsequently, decreases the production of biologically active angiotensin neuropeptides, including angiotensin II. Studies have shown the usefulness of renin inhibitors in hypertension, atherosclerosis, chronic kidney disease, cardiac hypertrophy and vascular inflammation.<sup><xref ref-type="bibr" rid="bibr10-1470320312460899">10</xref><xref ref-type="bibr" rid="bibr11-1470320312460899"/>
<xref ref-type="bibr" rid="bibr12-1470320312460899"/>–<xref ref-type="bibr" rid="bibr13-1470320312460899">13</xref></sup></p>
<p>In our previous studies, it was demonstrated that spironolactone (an aldosterone antagonist) and telmisartan (AT1 receptor antagonist) possess the ameliorative potential for attenuating neuropathic pain manifestations in a chronic constriction injury (CCI) model.<sup><xref ref-type="bibr" rid="bibr14-1470320312460899">14</xref>,<xref ref-type="bibr" rid="bibr15-1470320312460899">15</xref></sup> Since both aldosterone and AT1 receptors are part of the renin-angiotensin-aldosterone system, it is hypothesized that blocking the renin-angiotensin-aldosterone system at a very early stage by directly inhibiting renin with aliskiren may also attenuate neuropathic pain in CCI. Therefore, the present study was designed to explore the beneficial effects of aliskiren in attenuating neuropathic pain in CCI model in rats.</p>
</sec>
<sec id="section2-1470320312460899" sec-type="materials|methods">
<title>Material and methods</title>
<sec id="section3-1470320312460899">
<title>Experimental animals</title>
<p>Sprague-Dawley rats of either sex weighing 200–250 g (procured from Panjab University, Chandigarh, India) were employed in the present study. They were housed in an animal house with free access to water and standard laboratory chow diet. The rats were exposed to a normal cycle of light and dark. The experimental protocol was duly approved by the Institutional Animals Ethics Committee (IAEC) and the care of the animals was carried out as per the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment and Forest, Government of India (Reg. No. 107/1999/CPCSEA).</p>
</sec>
<sec id="section4-1470320312460899">
<title>Drugs and reagents</title>
<p>Aliskiren was obtained from Novartis, India and was dissolved in normal saline. Bovine serum albumin and Folin Ciocalteu’s phenol reagent were obtained from SD Fine, Mumbai, India. All of the chemicals used in the present study were of analytical grade. The Tumor necrosis factor-alpha (TNF-α) assay kit was procured from RayBio Inc., USA.</p>
</sec>
<sec id="section5-1470320312460899">
<title>CCI-induced neuropathic pain</title>
<p>Peripheral neuropathic pain was induced by CCI.<sup><xref ref-type="bibr" rid="bibr15-1470320312460899">15</xref>,<xref ref-type="bibr" rid="bibr16-1470320312460899">16</xref></sup> In brief, each rat was deeply anesthetized with chloral hydrate (350 mg/kg intraperitoneal (i.p.)) and the hair of the rat’s lower back and thigh were shaved. The skin of the lateral surface of the left thigh was incised and a cut made directly through the biceps femoris muscle to expose the sciatic nerve. Once exposed, the sciatic nerve was ligated with silk 4-0 thread at four sites with 1 mm gaps. The silk suture was used instead of chromic gut suture as it has been documented that the chromic gut suture initiates inflammatory reactions in the sciatic nerve.<sup><xref ref-type="bibr" rid="bibr17-1470320312460899">17</xref></sup> The ligatures were loosely tied until a short flick of the ipsilateral hind limb was observed. The muscle and skin were closed in two layers with the use of thread, and topical antibiotic was applied. All surgical procedures were carried out under normal sterile conditions. Due to the distinct development of postural defects in the paw of CCI control animals, the behavioral studies were not blinded for comparing normal control, sham control and CCI control groups. However, for all other groups the behavioral tests were blinded.</p>
</sec>
<sec id="section6-1470320312460899">
<title>Behavioral examination</title>
<sec id="section7-1470320312460899">
<title>Paw cold allodynia (acetone drop test)</title>
<p>Cold allodynia was assessed by spraying 100 μl of acetone onto the surface of the rat's paw (placed over a wire mesh) without touching the skin. The response of the rat to acetone was noted for 20 s and was graded on a four-point scale as defined by Flatters and Bennett<sup><xref ref-type="bibr" rid="bibr18-1470320312460899">18</xref></sup> (0: no response; 1: quick withdrawal, flick or stamp of the paw; 2: prolonged withdrawal or repeated flicking; and 3: repeated flicking of the paw with licking of the paw). Acetone was applied three times to the hind paw, with a gap of 5 min between the acetone applications and the individual scores noted in 20 s intervals were added to obtain a single score over a cumulative period of 60 s. The minimum score was 0, while the maximum possible score was 9.</p>
</sec>
<sec id="section8-1470320312460899">
<title>Mechanical hyperalgesia (pin prick test)</title>
<p>Mechanical hyperalgesia was assessed by the pinprick test as described by Erichsen and Blackburn-Munro.<sup><xref ref-type="bibr" rid="bibr19-1470320312460899">19</xref></sup> The surface of the injured hind paw was touched with the point of a bent gauge needle (at 90° to the syringe) at an intensity sufficient to produce a reflex withdrawal response. The paw withdrawal duration was recorded in seconds and the normal quick reflex withdrawal response was given the value of 0.5 s.</p>
</sec>
<sec id="section9-1470320312460899">
<title>Paw heat-hyperalgesia (hot plate test)</title>
<p>The thermal nociceptive threshold, as an index of thermal hyperalgesia, was assessed by the Eddy’s hot plate, maintained at temperature of 52.5±1.0°C. The rat was placed on the hot plate and withdrawal latency, with respect to licking of the hind paw, was recorded in seconds. The cut-off time of 15 s was maintained.<sup><xref ref-type="bibr" rid="bibr20-1470320312460899">20</xref></sup></p>
</sec>
<sec id="section10-1470320312460899">
<title>Mechanical allodynia (von Frey hair test)</title>
<p>Mechanical allodynia (non-noxious mechanical stimuli) was assessed as described by Chaplan and co-workers.<sup><xref ref-type="bibr" rid="bibr21-1470320312460899">21</xref></sup> Briefly, nylon filaments (von Frey hair), calibrated in terms of different bending forces, were applied to the mid plantar surface of left hind paw. The filaments were applied 10 times, starting with the softest and continuing in ascending order of stiffness. A brisk withdrawal of the left hind limb was considered a positive response. The criterion for the threshold value, in grams, was equal to the filament evoking a withdrawal threshold of the left hind paw five times out of 10 trials i.e. 50% response.</p>
</sec></sec>
<sec id="section11-1470320312460899">
<title>Cytokine and protein assay</title>
<p>All the animals were sacrificed and the sciatic nerve was isolated immediately for biochemical analysis. The sciatic nerve was homogenized in phosphate buffered saline, pH 7.4, and the homogenates were centrifuged at 1500 g at 4°C for 10 min and the supernatant was immediately used for protein estimation and TNF-α estimation.</p>
<sec id="section12-1470320312460899">
<title>Estimation of protein content</title>
<p>The protein concentration in the sciatic nerve was estimated according to the method of Lowry et al. (1951) using bovine serum albumin as a standard.<sup><xref ref-type="bibr" rid="bibr22-1470320312460899">22</xref></sup></p>
</sec>
<sec id="section13-1470320312460899">
<title>Estimation of TNF-α</title>
<p>TNF-α was estimated using a commercially available enzyme-linked immunosorbent assay (ELISA). The concentration of TNF-α was expressed in pg/mg of protein.</p>
</sec></sec>
<sec id="section14-1470320312460899">
<title>Experimental protocol</title>
<p>Twelve groups, each comprising six rats, were employed in the present study.</p>
<sec id="section15-1470320312460899">
<title>Group I: Normal control</title>
<p>Rats were not subjected to any treatment and were kept for 14 days. The behavioral tests were employed on day 0 (corresponding to the day before surgery in sham control) and day 14. Thereafter on day 14, the animals were sacrificed and the biochemical estimations were performed.</p>
</sec>
<sec id="section16-1470320312460899">
<title>Group II: Sham control</title>
<p>Rats were subjected to the surgical procedure to expose the left sciatic nerve on day 1 without any nerve ligation. The behavioral tests were done on day 0 (before surgery), and on day 14 and the biochemical analysis was done as described in group I.</p>
</sec>
<sec id="section17-1470320312460899">
<title>Group III: CCI control</title>
<p>Rats were subjected to the surgical procedure to expose and ligate the left sciatic nerve on day 1 as described earlier. The behavioral tests and the biochemical analysis were done as described in group I.</p>
</sec>
<sec id="section18-1470320312460899">
<title>Group IV–VI: Aliskiren (10, 25 and 50 mg/kg) in CCI control</title>
<p>Aliskiren (10, 25 and 50 mg/kg i.p.) was administered in CCI-subjected rats for 14 days, from day 1 (30 min prior to anesthesia for surgery) to day 14. The absolute bioavailability of aliskiren is 2.6%, accordingly it was administered by parenteral route in the present study. The behavioral tests and the biochemical analysis were done as described in group I.</p>
</sec>
<sec id="section19-1470320312460899">
<title>Group XIII: Vehicle in CCI control</title>
<p>Normal saline (1 ml/kg i.p.) was administered in CCI-subjected rats for 14 days, from day 1 (30 min prior to anesthesia for surgery) to day 14. The behavioral tests and the biochemical analysis were done as described in group I.</p>
</sec>
<sec id="section20-1470320312460899">
<title>Group IX: Aliskiren (50 mg/kg i.p.) per se</title>
<p>Aliskiren (50 mg/kg i.p.) was administered in normal rats for 14 days and the different behavioral tests and biochemical analysis were done as in described group I.</p>
</sec></sec>
<sec id="section21-1470320312460899">
<title>Statistical analysis</title>
<p>The results were expressed in mean±standard error of the mean (SEM) The data from behavioral tests were analyzed using a two way Analysis of variance (ANOVA), while the data from biochemical tests were analyzed using a one way ANOVA, followed by Bonferroni's post hoc test, using Graph pad prism Version-5.0 software. A <italic>p</italic>-value&lt; 0.05 was considered to be statistically significant.</p>
</sec></sec>
<sec id="section22-1470320312460899" sec-type="results">
<title>Results</title>
<p>All of the pain-related behavioral parameters were comparable between various groups at the starting day (data not shown).</p>
<sec id="section23-1470320312460899">
<title>Effect of aliskiren on hyperalgesia and allodynia in CCI-induced neuropathic pain</title>
<p>CCI resulted in significant development of cold allodynia (<xref ref-type="fig" rid="fig1-1470320312460899">Figure 1</xref>), mechanical allodynia (<xref ref-type="fig" rid="fig2-1470320312460899">Figure 2</xref>), mechanical hyperalgesia (<xref ref-type="fig" rid="fig3-1470320312460899">Figure 3</xref>) and heat hyperalgesia (<xref ref-type="fig" rid="fig4-1470320312460899">Figure 4</xref>) as compared to the sham control group, assessed by employing the acetone drop test, von Frey hair test, pin prick and hot plate tests, respectively. Administration of aliskiren (25 and 50 mg/kg i.p.) for 14 days, attenuated CCI-induced hyperalgesia and allodynia in a significant manner. Per se administration of aliskiren (50 mg/kg i.p.) did not modulate behavioral functions in normal rats. Administration of the vehicle alone did not alter CCI-induced hyperalgesia and allodynia.</p>
<fig id="fig1-1470320312460899" position="float">
<label>Figure 1.</label>
<caption>
<p>Effect of aliskiren on chronic constriction injury (CCI)-induced paw cold allodynia assessed by acetone drop test on day 14.</p>
<p>a: <italic>p</italic>&lt;0.05 vs sham control; b: <italic>p</italic>&lt;0.05 vs CCI; c: <italic>p&lt;</italic>0.05 vs aliskiren (25 mg/kg) in CCI.</p>
<p><italic>F</italic> (1,80)=1076.26 for days, <italic>p</italic>&lt;0.0001 and <italic>F</italic> (7,80)=120.00 for treatment, <italic>p</italic>&lt;0.0001.</p>
<p>Values are given as mean±Standard error of the mean (SEM), <italic>n</italic>=6 rats per group.</p>
</caption>
<graphic xlink:href="10.1177_1470320312460899-fig1.tif"/></fig>
<fig id="fig2-1470320312460899" position="float">
<label>Figure 2.</label>
<caption>
<p>Effect of aliskiren on chronic constriction injury (CCI)-induced mechanical allodynia assessed by von Frey hair test on day 14.</p>
<p>a: <italic>p</italic>&lt;0.05 vs sham control; b: <italic>p</italic>&lt;0.05 vs CCI; c: <italic>p&lt;</italic>0.05 vs aliskiren (25 mg/kg) in CCI.</p>
<p><italic>F</italic> (1,80)=84.98 for days, <italic>p</italic>&lt;0.0001 and <italic>F</italic> (7,80)=14.19 for treatment, <italic>p</italic>&lt;0.0001.</p>
<p>Values are given as mean±Standard error of the mean (SEM), <italic>n</italic>=6 rats per group;</p>
</caption>
<graphic xlink:href="10.1177_1470320312460899-fig2.tif"/></fig>
<fig id="fig3-1470320312460899" position="float">
<label>Figure 3.</label>
<caption>
<p>Effect of aliskiren on chronic constriction injury (CCI)-induced mechanical hyperalgesia assessed by pin prick test on day 14.</p>
<p>a: <italic>p</italic>&lt;0.05 vs sham control; b: <italic>p</italic>&lt;0.05 vs CCI; c: <italic>p&lt;</italic>0.05 vs aliskiren (25 mg/kg) in CCI.</p>
<p><italic>F</italic> (1,79)=1316.74 for days, <italic>p</italic>&lt;0.0001 and <italic>F</italic> (7,79)=165.50 for treatment, <italic>p</italic>&lt;0.0001.</p>
<p>Values are given in mean±SEM, <italic>n</italic>=6 rats per group;</p>
</caption>
<graphic xlink:href="10.1177_1470320312460899-fig3.tif"/></fig>
<fig id="fig4-1470320312460899" position="float">
<label>Figure 4.</label>
<caption>
<p>Effect of aliskiren on chronic constriction injury (CCI)-induced heat hyperalgesia assessed by Eddy’s hot plate test on day 14.</p>
<p>a: <italic>p</italic>&lt;0.05 vs sham control; b: <italic>p</italic>&lt;0.05 vs CCI; c: <italic>p&lt;</italic>0.05 vs aliskiren (25 mg/kg) in CCI.</p>
<p><italic>F</italic> (1, 80)=791.11 for days, <italic>p</italic>&lt;0.0001 and <italic>F</italic> (7, 80)=119.90 for treatment, <italic>p</italic>&lt;0.0001.</p>
<p>Values are given as mean±SEM, <italic>n</italic>=6 rats per group.</p>
</caption>
<graphic xlink:href="10.1177_1470320312460899-fig4.tif"/></fig>
</sec>
<sec id="section24-1470320312460899">
<title>Effect of aliskiren on TNF-α in CCI induced neuropathic pain</title>
<p>CCI significantly elevated TNF-α levels in the sciatic nerve on day 14 as compared to sham control rats. Administration of aliskiren (25 and 50 mg/kg) significantly attenuated the CCI-induced increase in TNF-α levels. Per se administration of aliskiren (50 mg/kg i.p.) and the vehicle only did not produce any effect on TNF-α in normal and CCI-subjected rats, respectively (<xref ref-type="fig" rid="fig5-1470320312460899">Figure 5</xref>).</p>
<fig id="fig5-1470320312460899" position="float">
<label>Figure 5.</label>
<caption>
<p>Effect of aliskiren on chronic constriction injury (CCI)-induced rise in Tumor necrosis factor-alpha (TNF-α) level in the sciatic nerve on day 14.</p>
<p>a: <italic>p</italic>&lt;0.05 vs sham control; b: <italic>p</italic>&lt;0.05 vs CCI; c: <italic>p</italic>&lt;0.05 vs aliskiren (25 mg/kg) in CCI.</p>
<p><italic>F</italic> (7,47)=19.83, <italic>p</italic>&lt;0.0001.</p>
<p>Values are given as mean±SEM, <italic>n</italic>=6 rats per group.</p>
</caption>
<graphic xlink:href="10.1177_1470320312460899-fig5.tif"/></fig>
</sec></sec>
<sec id="section25-1470320312460899" sec-type="discussion">
<title>Discussion</title>
<p>The CCI model is the most commonly employed animal neuropathic pain model of nerve damage-induced allodynia/hyperalgesia.<sup><xref ref-type="bibr" rid="bibr16-1470320312460899">16</xref>,<xref ref-type="bibr" rid="bibr23-1470320312460899">23</xref></sup> In this model, neuropathic pain is induced by entrapping the sciatic nerve through four loose ligatures and the model shares the pathophysiology of carpal tunnel syndrome in humans due to the entrapment of the median nerve in narrowing the carpal tunnel. Furthermore, this model has also been suggested as sharing the pathophysiology of the complex regional pain syndrome in humans.<sup><xref ref-type="bibr" rid="bibr16-1470320312460899">16</xref>,<xref ref-type="bibr" rid="bibr24-1470320312460899">24</xref></sup> In the present study, CCI led to the significant development of cold allodynia, mechanical allodynia, mechanical hyperalgesia, heat hyperalgesia assessed on day 14 after surgery. In our previous studies, the peak behavioral alterations were reported on day 14 after the nerve injury in the CCI model.<sup><xref ref-type="bibr" rid="bibr15-1470320312460899">15</xref></sup> Therefore, in the present study, the behavioral alterations were assessed on day 14 after CCI.</p>
<p>In the present investigation, the administration of aliskiren (25 and 50 mg/kg i.p.) for 14 days significantly attenuated CCI-induced behavioral alterations including paw cold allodynia, mechanical allodynia, mechanical and heat hyperalgesia. Aliskiren is a non-peptide, low molecular weight, direct renin inhibitor and reduces the formation of angiotensin II by inhibiting renin-mediated conversion of angiotensinogen to angiotensin I. Angiotensin II is a main final effector molecule of the renin–angiotensin system which in turn produces the majority of its effects through activation of angiotensin AT1 receptors.<sup><xref ref-type="bibr" rid="bibr2-1470320312460899">2</xref></sup> The repeated administration of angiotensin AT1 receptor blockers and angiotensin-converting enzyme (ACE) inhibitors such as spirapril, trandolapril and losartan has been documented to produce anti-nociceptive actions in mice.<sup><xref ref-type="bibr" rid="bibr25-1470320312460899">25</xref></sup> The studies have shown that the renin-angiotensin system has a clinically important role in migraine pathophysiology.<sup><xref ref-type="bibr" rid="bibr9-1470320312460899">9</xref></sup> Angiotensin AT1 receptor blockers and ACE inhibitors have potential in the prophylactic management of migraine. Various clinical studies have shown that ACE inhibitors, including enalpril and lisinopril, and angiotensin AT1 receptor blockers, including telmisartan, are effective in preventing the attacks of migraine.<sup><xref ref-type="bibr" rid="bibr26-1470320312460899">26</xref><xref ref-type="bibr" rid="bibr27-1470320312460899"/>
<xref ref-type="bibr" rid="bibr28-1470320312460899"/>–<xref ref-type="bibr" rid="bibr29-1470320312460899">29</xref></sup> The studies have shown the critical role of the renin-angiotensin system in the development of pancreatic neuropathy in experimental acute/chronic pancreatitis models as well in clinical pancreatitis.<sup><xref ref-type="bibr" rid="bibr8-1470320312460899">8</xref>,<xref ref-type="bibr" rid="bibr30-1470320312460899">30</xref>,<xref ref-type="bibr" rid="bibr31-1470320312460899">31</xref></sup> In our previous study, telmisartan was reported to attenuate neuropathic pain behavior in the CCI model.<sup><xref ref-type="bibr" rid="bibr15-1470320312460899">15</xref></sup> This is the first experimental study reporting the potential of aliskiren, a direct renin inhibitor, in attenuating neuropathic pain manifestations in the CCI model.</p>
<p>In the present study, CCI-induced neuropathic pain was also associated with a rise in the TNF-α level in the sciatic nerve. TNF-α appears early in the cytokine cascade and therefore it has been considered as a prototype pro-inflammatory mediator. The role of TNF-α has been well documented in peripheral, as well as central, sensitization in neuropathic pain.<sup><xref ref-type="bibr" rid="bibr32-1470320312460899">32</xref></sup> However, administration of aliskiren (25 and 50 mg/kg i.p.) attenuated a CCI-induced rise in TNF-α levels. There have been studies documenting the potent anti-inflammatory potential of aliskiren through inhibiting leukocyte adhesion, preventing oxidative stress and decreasing the production of inflammatory cytokines including TNF-α.<sup><xref ref-type="bibr" rid="bibr13-1470320312460899">13</xref>,<xref ref-type="bibr" rid="bibr33-1470320312460899">33</xref>,<xref ref-type="bibr" rid="bibr34-1470320312460899">34</xref></sup> Furthermore, aliskiren has also been shown to attenuate TNF-α mediated deleterious effects on different body systems including the coagulation pathway in human umbilical vein endothelial cells.<sup><xref ref-type="bibr" rid="bibr34-1470320312460899">34</xref></sup> An aliskiren-induced decrease in inflammatory mediators in the present study may possibly be due to a decrease in angiotensin II levels as this has been well documented to modulate several steps of the inflammatory response including vascular permeability, leukocyte infiltration, production of reactive oxygen species and inflammatory cytokines.<sup><xref ref-type="bibr" rid="bibr35-1470320312460899">35</xref></sup> Earlier studies had documented the presence of angiotensin AT1 receptors in inflammatory cells.<sup><xref ref-type="bibr" rid="bibr36-1470320312460899">36</xref>,<xref ref-type="bibr" rid="bibr37-1470320312460899">37</xref></sup> Based on these studies, it may be tentatively proposed that an aliskiren-mediated decrease in angiotensin II synthesis may be responsible for a decrease in inflammatory cytokines and for beneficial effects in neuropathic pain.</p>
<p>The CCI has been described as mimicking the complex regional pain syndrome in humans which is characterized by the activation of the sympathetic nervous system that in turn activates the renin-angiotensin system.<sup><xref ref-type="bibr" rid="bibr16-1470320312460899">16</xref>,<xref ref-type="bibr" rid="bibr24-1470320312460899">24</xref></sup> In our previous studies, spironolactone and telmisartan were shown to attenuate neuropathic pain in the CCI model thus suggesting a key role of the renin-angiotensin-aldosterone system in the pathophysiology of pain development.<sup><xref ref-type="bibr" rid="bibr14-1470320312460899">14</xref>,<xref ref-type="bibr" rid="bibr15-1470320312460899">15</xref></sup> The results of our present study, demonstrating the attenuation of neuropathic pain by aliskiren, further support the hypothesis suggesting the key role of the renin-angiotensin-aldosterone system in the pathogenesis of neuropathic pain. Aliskiren, being a direct renin inhibitor, inhibits the renin-angiotensin-aldosterone system at a very early stage and thus decreased levels of angiotensin II and aldosterone may be responsible for the beneficial effects observed in neuropathic pain. However, there have been studies documenting how aliskiren produces beneficial effects in diabetic nephropathy by directly activating the pro-renin receptors and decreasing the inflammatory cytokines including TNF-α and Interleukin-beta (IL-β), independent of angiotensin II.<sup><xref ref-type="bibr" rid="bibr38-1470320312460899">38</xref>,<xref ref-type="bibr" rid="bibr39-1470320312460899">39</xref></sup> Therefore in the present study, the direct role of pro-renin receptors in decreasing inflammatory cytokines and producing beneficial effects in neuropathic pain may not be completely ruled out. The ability of aliskiren to cross the blood brain barrier is not clear yet<sup><xref ref-type="bibr" rid="bibr40-1470320312460899">40</xref></sup> and therefore the precise site of action, central or peripheral, may not be clearly elucidated and needs further investigation. Based on these findings, it may be proposed that nerve injury-induced activation of the sympathetic nervous system causes activation of the renin-angiotensin-aldosterone system which in turn may be responsible in the development of neuropathic pain.</p>
</sec>
<sec id="section26-1470320312460899" sec-type="conclusions">
<title>Conclusion</title>
<p>Aliskiren attenuates neuropathic pain manifestation in the CCI model which may possibly be attributed to its ability to decrease the release of pro-inflammatory mediators in a nerve injury condition.</p>
</sec>
</body>
<back>
<ack><p>The authors are grateful to the Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India for providing technical facilities.</p></ack>
<fn-group>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>None declared.</p></fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The research project was funded by the Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320312460899">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmader</surname><given-names>KE</given-names></name>
</person-group>. <article-title>Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy</article-title>. <source>Clin J Pain</source> <year>2002</year>; <volume>18</volume>: <fpage>350</fpage>–<lpage>354</lpage>.</citation>
</ref>
<ref id="bibr2-1470320312460899">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferrario</surname><given-names>CM</given-names></name>
</person-group>. <article-title>Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research</article-title>. <source>J. Renin Angiotensin Aldosterone Syst</source> <year>2006</year>; <volume>7</volume>: <fpage>3</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr3-1470320312460899">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simões E Silva AC</surname></name>
<name><surname>Flynn</surname><given-names>JT</given-names></name>
</person-group>. <article-title>The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease</article-title>. <source>Pediatr Nephrol</source> <year>2012</year>; <volume>27</volume>: <fpage>1835</fpage>–<lpage>1845</lpage>.</citation>
</ref>
<ref id="bibr4-1470320312460899">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fukami</surname><given-names>K</given-names></name>
<name><surname>Yamagishi</surname><given-names>S</given-names></name>
<name><surname>Ueda</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Role of AGEs in diabetic nephropathy</article-title>. <source>Curr Pharm Des</source> <year>2008</year>; <volume>14</volume>: <fpage>946</fpage>–<lpage>952</lpage>.</citation>
</ref>
<ref id="bibr5-1470320312460899">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sata</surname><given-names>M</given-names></name>
<name><surname>Fukuda</surname><given-names>D</given-names></name>
</person-group>. <article-title>Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis</article-title>. <source>J. Med Invest</source> <year>2010</year>; <volume>57</volume>: <fpage>12</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr6-1470320312460899">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stiefel</surname><given-names>P</given-names></name>
<name><surname>Vallejo-Vaz</surname><given-names>AJ</given-names></name>
<name><surname>García-Morillo</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Role of the renin-angiotensin system and aldosterone on cardiometabolic syndrome</article-title>. <source>Int J Hypertens</source> <year>2011</year>; <fpage>685238</fpage>.</citation>
</ref>
<ref id="bibr7-1470320312460899">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurihara</surname><given-names>T</given-names></name>
<name><surname>Ozawa</surname><given-names>Y</given-names></name>
<name><surname>Ishida</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Renin angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction</article-title>. <source>Int J Inflam</source> <year>2012</year>; <fpage>581695</fpage>.</citation>
</ref>
<ref id="bibr8-1470320312460899">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oruc</surname><given-names>N</given-names></name>
<name><surname>Ozutemiz</surname><given-names>O</given-names></name>
<name><surname>Nart</surname><given-names>D</given-names></name>
<etal/></person-group>. <article-title>Inhibition of renin-angiotensin system in experimental acute pancreatitis in rats: a new therapeutic target?</article-title> <source>Exp Toxicol Pathol</source> <year>2010</year>; <volume>62</volume>: <fpage>353</fpage>–<lpage>360</lpage>.</citation>
</ref>
<ref id="bibr9-1470320312460899">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tronvik</surname><given-names>E</given-names></name>
<name><surname>Stovner</surname><given-names>LJ</given-names></name>
<name><surname>Schrader</surname><given-names>H</given-names></name>
<etal/></person-group>. <article-title>Involvement of the renin-angiotensin system in migraine</article-title>. <source>J Hypertens Suppl</source> <year>2006</year>; <volume>24</volume>: <fpage>S139</fpage>–<lpage>S143</lpage>.</citation>
</ref>
<ref id="bibr10-1470320312460899">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wood</surname><given-names>JM</given-names></name>
<name><surname>Cumin</surname><given-names>F</given-names></name>
<name><surname>Maibaum</surname><given-names>J</given-names></name>
</person-group>. <article-title>Pharmacology of renin inhibitors and their application to the treatment of hypertension</article-title>. <source>Pharmacol Ther</source> <year>1994</year>; <volume>61</volume>: <fpage>325</fpage>–<lpage>344</lpage>.</citation>
</ref>
<ref id="bibr11-1470320312460899">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lu</surname><given-names>H</given-names></name>
<name><surname>Rateri</surname><given-names>DL</given-names></name>
<name><surname>Feldman</surname><given-names>DL</given-names></name>
<etal/></person-group>. <article-title>Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice</article-title>. <source>J Clin Invest</source> <year>2008</year>; <volume>118</volume>: <fpage>984</fpage>–<lpage>993</lpage>.</citation>
</ref>
<ref id="bibr12-1470320312460899">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Campos</surname><given-names>LA</given-names></name>
<name><surname>Bader</surname><given-names>M</given-names></name>
<name><surname>Baltatu</surname><given-names>OC</given-names></name>
</person-group>. <article-title>Brain renin-angiotensin system in hypertension, cardiac hypertrophy, and heart failure</article-title>. <source>Front Physiol</source> <year>2011</year>; <volume>2</volume>: <fpage>1</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr13-1470320312460899">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ino</surname><given-names>J</given-names></name>
<name><surname>Kojima</surname><given-names>C</given-names></name>
<name><surname>Osaka</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Dynamic observation of mechanically injured mouse femoral artery reveals an anti-inflammatory effect of renin inhibitor</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2009</year>; <volume>29</volume>: <fpage>1858</fpage>–<lpage>1863</lpage>.</citation>
</ref>
<ref id="bibr14-1470320312460899">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jaggi</surname><given-names>AS</given-names></name>
<name><surname>Singh</surname><given-names>N</given-names></name>
</person-group>. <article-title>Differential effect of spironolactone in chronic constriction injury and vincristine-induced neuropathic pain in rats</article-title>. <source>Eur J Pharmacol</source> <year>2010</year>; <volume>648</volume>: <fpage>102</fpage>–<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr15-1470320312460899">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jaggi</surname><given-names>AS</given-names></name>
<name><surname>Singh</surname><given-names>N</given-names></name>
</person-group>. <article-title>Exploring the potential of telmisartan in chronic constriction injury-induced neuropathic pain in rats</article-title>. <source>Eur J Pharmacol</source> <year>2011</year>; <volume>667</volume>: <fpage>215</fpage>–<lpage>221</lpage>.</citation>
</ref>
<ref id="bibr16-1470320312460899">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bennett</surname><given-names>GJ</given-names></name>
<name><surname>Xie</surname><given-names>YK</given-names></name>
</person-group>. <article-title>A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man</article-title>. <source>Pain</source> <year>1998</year>; <volume>33</volume>: <fpage>87</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr17-1470320312460899">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maves</surname><given-names>TJ</given-names></name>
<name><surname>Pechman</surname><given-names>PS</given-names></name>
<name><surname>Gebhart</surname><given-names>GF</given-names></name>
<etal/></person-group>. <article-title>Possible chemical contribution from chromic gut sutures produces disorders of pain sensation like those seen in man</article-title>. <source>Pain</source> <year>1993</year>; <volume>54</volume>: <fpage>57</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr18-1470320312460899">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Flatters</surname><given-names>SJ</given-names></name>
<name><surname>Bennett</surname><given-names>GJ</given-names></name>
</person-group>. <article-title>Ethosuximide reverses paclitaxel- and vincritine-induced painful peripheral neuropathy</article-title>. <source>Pain</source> <year>2004</year>; <volume>109</volume>: <fpage>150</fpage>–<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr19-1470320312460899">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Erichsen</surname><given-names>HK</given-names></name>
<name><surname>Blackburn-Munro</surname><given-names>G</given-names></name>
</person-group>. <article-title>Pharmacological characterization of the spared nerve injury model of neuropathic pain</article-title>. <source>Pain</source> <year>2002</year>; <volume>98</volume>: <fpage>151</fpage>–<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr20-1470320312460899">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jain</surname><given-names>V</given-names></name>
<name><surname>Jaggi</surname><given-names>AS</given-names></name>
<name><surname>Singh</surname><given-names>N</given-names></name>
</person-group>. <article-title>Ameliorative potential of rosiglitazone in tibial and sural nerve transection-induced painful neuropathy in rats</article-title>. <source>Pharmacol Res</source> <year>2009</year>; <volume>59</volume>: <fpage>385</fpage>–<lpage>392</lpage></citation>
</ref>
<ref id="bibr21-1470320312460899">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chaplan</surname><given-names>SR</given-names></name>
<name><surname>Bach</surname><given-names>FW</given-names></name>
<name><surname>Pogrel</surname><given-names>JW</given-names></name>
<etal/></person-group>. <article-title>Quantitative assessment of tactile allodynia in the rat paw</article-title>. <source>J Neurosci Methods</source> <year>1994</year>; <volume>53</volume>: <fpage>55</fpage>–<lpage>63</lpage></citation>
</ref>
<ref id="bibr22-1470320312460899">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lowry</surname><given-names>OH</given-names></name>
<name><surname>Rosenbrough</surname><given-names>NJ</given-names></name>
<name><surname>Farr</surname><given-names>AL</given-names></name>
<etal/></person-group>. <article-title>Protein measurement with folin phenol reagent</article-title>. <source>J Biol Chem</source> <year>1951</year>; <volume>193</volume>: <fpage>265</fpage>–<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr23-1470320312460899">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jaggi</surname><given-names>AS</given-names></name>
<name><surname>Jain</surname><given-names>V</given-names></name>
<name><surname>Singh</surname><given-names>N</given-names></name>
</person-group>. <article-title>Animal models of neuropathic pain</article-title>. <source>Fundam Clin Pharmacol</source> <year>2011</year>; <volume>25</volume>: <fpage>1</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr24-1470320312460899">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jin</surname><given-names>Y</given-names></name>
<name><surname>Sato</surname><given-names>J</given-names></name>
<name><surname>Yamazaki</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Changes in cardiovascular parameters and plasma norepinephrine level in rats after chronic constriction injury on the sciatic nerve</article-title>. <source>Pain</source> <year>2008</year>; <volume>135</volume>: <fpage>221</fpage>–<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr25-1470320312460899">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takai</surname><given-names>S</given-names></name>
<name><surname>Song</surname><given-names>K</given-names></name>
<name><surname>Tanaka</surname><given-names>T</given-names></name>
<etal/></person-group>. <article-title>Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice</article-title>. <source>Life Sci</source> <year>1996</year>; <volume>59</volume>: <fpage>PL331</fpage>–<lpage>PL336</lpage>.</citation>
</ref>
<ref id="bibr26-1470320312460899">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Camarda</surname><given-names>R</given-names></name>
<name><surname>Monastero</surname><given-names>R</given-names></name>
<name><surname>Mannino</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Enalapril prophylaxis for migraine with aura</article-title>. <source>Headache</source> <year>2003</year>; <volume>43</volume>: <fpage>170</fpage>.</citation>
</ref>
<ref id="bibr27-1470320312460899">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nandha</surname><given-names>R</given-names></name>
<name><surname>Singh</surname><given-names>H</given-names></name>
</person-group>. <article-title>Renin angiotensin system: a novel target for migraine prophylaxis</article-title>. <source>Indian J Pharmacol</source> <year>2012</year>; <volume>44</volume>: <fpage>157</fpage>–<lpage>160</lpage>.</citation>
</ref>
<ref id="bibr28-1470320312460899">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schuh-Hofer</surname><given-names>S</given-names></name>
<name><surname>Flach</surname><given-names>U</given-names></name>
<name><surname>Meisel</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>Efficacy of lisinopril in migraine prophylaxis–an open label study</article-title>. <source>Eur J Neurol</source> <year>2007</year>; <volume>14</volume>: <fpage>701</fpage>–<lpage>703</lpage>.</citation>
</ref>
<ref id="bibr29-1470320312460899">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gales</surname><given-names>BJ</given-names></name>
<name><surname>Bailey</surname><given-names>EK</given-names></name>
<name><surname>Reed</surname><given-names>AN</given-names></name>
<etal/></person-group>. <article-title>Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines</article-title>. <source>Ann Pharmacother</source> <year>2010</year>; <volume>44</volume>: <fpage>360</fpage>–<lpage>366</lpage>.</citation>
</ref>
<ref id="bibr30-1470320312460899">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ceyhan</surname><given-names>GO</given-names></name>
<name><surname>Michalski</surname><given-names>CW</given-names></name>
<name><surname>Demir</surname><given-names>I</given-names></name>
<etal/></person-group>. <article-title>Pancreatic pain</article-title>. <source>Best Pract Res Clin Gastroenterol</source> <year>2008</year>; <volume>22</volume>: <fpage>31</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr31-1470320312460899">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Demir</surname><given-names>IE</given-names></name>
<name><surname>Tieftrunk</surname><given-names>E</given-names></name>
<name><surname>Maak</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Pain mechanisms in chronic pancreatitis: of a master and his fire</article-title>. <source>Langenbecks Arch Surg</source> <year>2011</year>; <volume>396</volume>: <fpage>151</fpage>–<lpage>160</lpage>.</citation>
</ref>
<ref id="bibr32-1470320312460899">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leung</surname><given-names>L</given-names></name>
<name><surname>Cahill</surname><given-names>CM</given-names></name>
</person-group>. <article-title>TNF-alpha and neuropathic pain-a review</article-title>. <source>J Neuroinflammation</source> <year>2010</year>; <volume>7</volume>: <fpage>1</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr33-1470320312460899">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Higashikuni</surname><given-names>Y</given-names></name>
<name><surname>Takaoka</surname><given-names>M</given-names></name>
<name><surname>Iwata</surname><given-names>H</given-names></name>
<etal/></person-group>. <article-title>Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice</article-title>. <source>Hypertens Res</source> <year>2012</year>; <volume>35</volume>: <fpage>62</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr34-1470320312460899">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Del Fiorentino</surname><given-names>A</given-names></name>
<name><surname>Cianchetti</surname><given-names>S</given-names></name>
<name><surname>Celi</surname><given-names>A</given-names></name>
</person-group>. <article-title>Aliskiren, a renin inhibitor, downregulates TNF-alpha-induced tissue factor expression in HUVECS</article-title>. <source>J Renin Angiotensin Aldosterone Syst</source> <year>2010</year>; <volume>11</volume>: <fpage>243</fpage>–<lpage>247</lpage>.</citation>
</ref>
<ref id="bibr35-1470320312460899">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>ZJ</given-names></name>
<name><surname>Vapaatalo</surname><given-names>H</given-names></name>
<name><surname>Mervaala</surname><given-names>E</given-names></name>
</person-group>. <article-title>Angiotensin II and vascular inflammation</article-title>. <source>Med Sci Monit</source> <year>2005</year>; <volume>11</volume>: <fpage>RA194</fpage>–<lpage>RA205</lpage>.</citation>
</ref>
<ref id="bibr36-1470320312460899">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kitazono</surname><given-names>T</given-names></name>
<name><surname>Padgett</surname><given-names>RC</given-names></name>
<name><surname>Armstrong</surname><given-names>ML</given-names></name>
<etal/></person-group>. <article-title>Evidence that angiotensin II is present in human monocytes</article-title>. <source>Circulation</source> <year>1995</year>; <volume>91</volume>: <fpage>1129</fpage>–<lpage>1134</lpage>.</citation>
</ref>
<ref id="bibr37-1470320312460899">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Potter</surname><given-names>DD</given-names></name>
<name><surname>Sobey</surname><given-names>CG</given-names></name>
<name><surname>Tompkins</surname><given-names>PK</given-names></name>
<etal/></person-group>. <article-title>Evidence that macrophages in atherosclerotic lesions contain angiotensin II</article-title>. <source>Circulation</source> <year>1998</year>; <volume>98</volume>: <fpage>800</fpage>–<lpage>807</lpage>.</citation>
</ref>
<ref id="bibr38-1470320312460899">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Feldman</surname><given-names>DL</given-names></name>
<name><surname>Jin</surname><given-names>L</given-names></name>
<name><surname>Xuan</surname><given-names>H</given-names></name>
<etal/></person-group>. <article-title>Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats</article-title>. <source>Hypertension</source> <year>2008</year>; <volume>52</volume>: <fpage>130</fpage>–<lpage>136</lpage>.</citation>
</ref>
<ref id="bibr39-1470320312460899">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matavelli</surname><given-names>LC</given-names></name>
<name><surname>Huang</surname><given-names>J</given-names></name>
<name><surname>Siragy</surname><given-names>HM</given-names></name>
</person-group>. <article-title>(Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation</article-title>. <source>Clin Exp Pharmacol Physiol</source> <year>2010</year>; <volume>37</volume>: <fpage>277</fpage>–<lpage>282</lpage>.</citation>
</ref>
<ref id="bibr40-1470320312460899">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmerbach</surname><given-names>K</given-names></name>
<name><surname>Pfab</surname><given-names>T</given-names></name>
<name><surname>Zhao</surname><given-names>Y</given-names></name>
<etal/></person-group>. <article-title>Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes</article-title>. <source>PLoS One</source> <year>2010</year>; <volume>5</volume>: <fpage>e15052</fpage>.</citation>
</ref></ref-list>
</back>
</article>